HSALIHI@EC2702A

Alibaba Health Releases FY2026 Results, Launches Medical AI 'Hydrogen Ion' and Unveils New Strategy

Alibaba Health to unify B2C and O2O pharmaceutical business segments for synergy

Alibaba Health shares drop over 4% after annual report; Citi and BofA issue ratings

ALI HEALTH released FY2026 Q3 earnings on May 14 (BJT), actual revenue HKD 9.763 B, actual EPS HKD 0.0229

ALI HEALTH released FY2026 9 Months earnings on May 14 (BJT), actual revenue HKD 28.03 B, actual EPS HKD 0.1085

ALI HEALTH released FY2026 Q4 earnings on May 14 After-Market (BJT), actual revenue HKD 9.953 B, actual EPS HKD 0.0234

ALI HEALTH released FY2026 annual earnings on May 14, 2026, after-market BJT: Actual Revenue HKD 37.98 B (Forecast HKD 39.87 B), Actual EPS HKD 0.1324 (Forecast HKD 0.1584)

Ali Health Information Technology's Final Special Dividend to be Funded by Reduction of Share Premium Account Balance

AliHealth Q1 2026 Net Profit Hits 1.936 Billion RMB, Up 35.2% YoY

Ali Health Information Technology Announces Full-Year Revenue of 34.2551 Billion RMB

AliHealth reports full-year gross margin of 24%, estimates 24.6%

Alibaba Health Launches Medical AI 'H Ion' and Reaches an Exclusive Partnership with BMJ Group

ALI HEALTH to Release FY2026 Earnings on May 14 After-Market (BJT), Forecast Revenue HKD 40.35 B, EPS HKD 0.1601

Morgan Stanley Cuts Alibab Health's Earnings Forecast and Maintains 'Reduce' Rating

Great Wall Securities Reaffirms Alibaba Health's Revenue Growth Target for FY2026 and Cuts Net Profit Growth Target

Alibaba's ATH Innovation Department's AI Model HappyHorse to Soon Open API

Goldman Sachs Downgrades Alibaba Health's Target Price to HKD 4.8

CLSA Downgrades Alibaba Health's Profit Forecast and Target Price

Alibaba Health and Novartis Announce Chronic Spontaneous Urticaria Digital Chronic Disease Collaboration

Alibaba CEO Wu Y 昺 Launches Enterprise AI-Native Work Platform “Wukong”

RADIANCE HLDGS

ANCHORSTONE

RIVERINE CHINA

REACH NEW HLDGS

FINELAND LIVING

NUR HOLDINGS

GOLDEN LEAF INT

UBOT HOLDING

MAN YUE TECH

00241

Qianwen has partnered with the National Medical Products Administration's Information Center to integrate millions of data records on drugs, cosmetics, and medical devices. This collaboration will enhance medication guidance, verify national approval information, and help users avoid counterfeit products. Qianwen will also provide insights on the suitability of various products and devices, while continuously updating its database in line with the Information Center.

AASTOCKS News

ALI HEALTH

Qianwen Partners with National Medical Products Administration Information Center, Integrates Authoritative Drug and Other Data

00HSI

At midday, HSI fell 229 points (0.9%) to 26,160, while HSTI dropped 63 points (1.3%) to 5,012. Notable declines included ALI HEALTH down over 6%, and other heavyweights like MEITUAN and BABA also saw losses. Conversely, SMIC and WUXI BIO experienced gains. Short selling activity was significant across various stocks.

Hang Seng Index

Hang Seng China Enterprises Index

MEITUAN

BABA-W

Alibaba

XIAOMI-W

TENCENT

JD LOGISTICS

INNOVENT BIO

JD HEALTH

SMIC

BEKE-W

CHINAHONGQIAO

ZIJIN MINING

SBP GROUP

WUXI BIO

BEONE MEDICINES

Beigene

PEGBIO CO-B

CARSGEN-B

MEITUAN-WR

Meituan

Meituan HK SDR 5to1

BABA-WR

Alibaba HK SDR 5to1

Xiaomi Corporation

XIAOMI-WR

Xiaomi HK SDR 2to1

Tencent

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

JD HEALTH-R

SMIC HK SDR 5to1

Zijin Mining

WuXi Biologics

BeOne Medicines

HSI Closes Midday at 26,160, Down 229 pts; HSTI Closes Midday at 5,012, Down 63 pts; ALI HEALTH Down over 6%

ALI HEALTHshares fell over 4% following the announcement of its full-year results, which showed a 12% revenue increase to RMB34.255 billion and a 35.2% rise in net profit to RMB1.936 billion. Citi noted the results were in line with expectations, while BofA highlighted a positive surprise from a special dividend. Citi set a target price of HKD9, while BofA maintained a target of HKD6.

Citigroup

Bank of America

CITIGROUP INC 6.250 NON CUM SER II PFD WI

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

ALI HEALTH Dives 4%+ as Citi Says Results In Line; BofAS Notes Surprise from Spec. Div.

512010

516610

159929

510660

Alibaba Health reported a 12% revenue increase to RMB34.26B and a 35.2% rise in net profit to RMB1.94B, driven by direct sales, digital services, and new medical AI models. CFO Tu Yanwu has resigned, with no details on succession provided, raising concerns about leadership risk. The company will pay a final special dividend by reducing its share premium account balance.

TradingView

E Fund CSI 300 Health Care ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

China Universal 800 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Key facts: Alibaba Health 34.26B rev; net +35% to 1.94B; CFO exits; dividend via premium

513120

ALI HEALTHhas proposed to reduce its share premium by approximately RMB10 billion to fund a total dividend of RMB19.47 cents per share, which includes a final dividend of RMB5.95 cents and a special dividend of RMB13.52 cents. This decision comes as the company faces insufficient contributed surplus for distribution as of March 31, 2026. The reduction will allow the company to offset accumulated losses and distribute funds to shareholders.

GF CSI HK Innovative Drugs Industry ETF(QDII)

ALI HEALTH Proposes to Reduce RMB10B Share Premium to Fund Dividend

Alibaba Health Information Technology reported a 12% revenue increase to RMB34.26 billion and a 35.2% rise in net profit to RMB1.94 billion for FY2026. Adjusted net profit grew 19.3%, supported by user growth on its healthcare platforms. The company is advancing its smart healthcare initiatives and launched a model for medical professionals. Despite positive growth, analysts rate the stock as a Sell with a price target of HK$4.60. Alibaba Health operates in the Internet healthcare sector, focusing on e-commerce and smart healthcare solutions.

Tip Ranks

Alibaba Health Delivers Strong FY2026 Profit Growth and Advances Smart Healthcare Push

Alibaba Health Information Technology has declared a final ordinary cash dividend of RMB 0.0595 per share for FY2026, pending shareholder approval on 7 August 2026. The ex-dividend date is 12 August, with a record date of 13 August and payment scheduled for 2 September 2026. The company has appointed Tricor Investor Services Limited as its share registrar. The latest analyst rating for the stock (HK:0241) is a Sell with a price target of HK$4.60. Alibaba Health focuses on technology-enabled healthcare solutions in mainland China and other markets.

Alibaba Health Declares Final Dividend for FY2026

HSALIHI@EC2702A(29309.HK)